Cardax, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CDXI research report →
Companywww.cardaxpharma.com
Cardax, Inc. , a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity.
- CEO
- David G. Watumull
- IPO
- 2013
- Employees
- 10
- HQ
- Honolulu, HI, US
Price Chart
Valuation
- Market Cap
- $80
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -1.81
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 63.61%
- Op Margin
- -568.26%
- Net Margin
- -938.04%
- ROE
- 58.12%
- ROIC
- 57.33%
Growth & Income
- Revenue
- $538.95K · -24.19%
- Net Income
- $-5,055,507 · 0.74%
- EPS
- $-6.79 · 19.17%
- Op Income
- $-3,062,636
- FCF YoY
- 49.61%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -13.76
- Avg Volume
- 11
Get TickerSpark's AI analysis on CDXI
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 24, 14 | PAULSON CAPITAL (DELAWARE) CORP. | buy | 500,000 |
| Feb 24, 14 | Paulson Cardax Investments 1 LLC | buy | 500,000 |
| Feb 7, 14 | Paulson Cardax Investments 1 LLC | other | 1,068,477 |
| Feb 7, 14 | PAULSON CAPITAL (DELAWARE) CORP. | other | 1,068,477 |
| Feb 7, 14 | PAULSON CAPITAL (DELAWARE) CORP. | other | 0 |
| Feb 7, 14 | PAULSON CAPITAL (DELAWARE) CORP. | other | 0 |
| Feb 7, 14 | PAULSON CAPITAL (DELAWARE) CORP. | other | 3,872,434 |
Our CDXI Coverage
We haven't published any research on CDXI yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CDXI Report →